{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ivacaftor+75+mg%2F150+mg", "query": { "intervention": "Ivacaftor 75 mg/150 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-02T03:56:35.864Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00457821", "title": "Safety Study of Ivacaftor in Subjects With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor 25 mg/75 mg", "type": "DRUG" }, { "name": "Ivacaftor 75 mg/150 mg", "type": "DRUG" }, { "name": "Ivacaftor 150 mg or 250 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2007-05", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00457821" }, { "nct_id": "NCT04183790", "title": "Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 64, "start_date": "2020-02-17", "completion_date": "2024-02-24", "has_results": true, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 13, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04183790" }, { "nct_id": "NCT03506061", "title": "Trikafta in Cystic Fibrosis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Trikafta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 42, "start_date": "2019-09-04", "completion_date": "2024-02-13", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Atlanta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03506061" }, { "nct_id": "NCT05743946", "title": "Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Non-cystic Fibrosis Bronchiectasis" ], "interventions": [ { "name": "Trikafta", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2023-04-18", "completion_date": "2025-12-23", "has_results": false, "last_update_posted_date": "2026-02-09", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05743946" }, { "nct_id": "NCT03601637", "title": "Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "LUM", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "12 Months to 23 Months" }, "enrollment_count": 61, "start_date": "2018-09-07", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03601637" }, { "nct_id": "NCT03691779", "title": "Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "ELX/TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 71, "start_date": "2018-10-02", "completion_date": "2020-08-07", "has_results": true, "last_update_posted_date": "2021-10-22", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 13, "location_summary": "Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03691779" }, { "nct_id": "NCT02953314", "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ", "type": "DRUG" }, { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 83, "start_date": "2016-11", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02953314" }, { "nct_id": "NCT04235140", "title": "Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "LUM/IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 52, "start_date": "2020-02-24", "completion_date": "2023-08-22", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04235140" }, { "nct_id": "NCT01946412", "title": "Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Ivacaftor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 33, "start_date": "2013-12", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Denver, Colorado • Atlanta, Georgia + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946412" }, { "nct_id": "NCT03537651", "title": "A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "TEZ/IVA", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 130, "start_date": "2018-04-25", "completion_date": "2023-09-29", "has_results": true, "last_update_posted_date": "2024-04-19", "last_synced_at": "2026-10-02T03:56:35.864Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537651" } ] }